Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas
This study is ongoing, but not recruiting participants.
Study NCT00012181 Information provided by National Cancer Institute (NCI)
First Received: March 3, 2001 Last Updated: July 23, 2008
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Childhood Germ Cell Tumor
Kidney Cancer
Liver Cancer
Lymphoma
Neuroblastoma
Retinoblastoma
Sarcoma
Additional conditions recognized in this trial
Carcinoma, Renal Cell
Central Nervous System Neoplasms
Kidney Neoplasms
Liver Neoplasms
Neoplasms, Germ Cell and Embryonal
Nervous System Neoplasms
More general conditions related to this trial
Adenocarcinoma
Carcinoma
Digestive System Diseases
Digestive System Neoplasms
Eye Diseases
Eye Neoplasms
Immune System Diseases
Immunoproliferative Disorders
Kidney Diseases
Liver Diseases
Lymphatic Diseases
Lymphoproliferative Disorders
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Connective and Soft Tissue
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Neoplasms, Neuroepithelial
Nervous System Diseases
Neuroectodermal Tumors
Neuroectodermal Tumors, Primitive
Neuroectodermal Tumors, Primitive, Peripheral
Retinal Diseases
Retinal Neoplasms
Urogenital Neoplasms
Urologic Diseases
Urologic Neoplasms
Interventions listed in this trial
alvocidib
Additional drug interventions recognized in this trial
Flavopiridol
More general drug interventions related to this trial
Antineoplastic Agents
Enzyme Inhibitors
Growth Inhibitors
Growth Substances
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Protein Kinase Inhibitors
Therapeutic Uses
Sponsors listed in this trial
Children's Oncology Group
National Cancer Institute (NCI)
Back to top of Main Content
